| Literature DB >> 34307661 |
Junshen Huang1, Yuxi Li1, Ziwei Ye2, Ziying Cheng1, Jiajun Huang1, Shixin Lu1, Kaihui Su1, Yuwei Liang1, Ming Li1, Lin Huang1.
Abstract
Low back pain which resulted from intervertebral disc degeneration (IDD) is a common health problem that afflicts people all over the world. Due to the lack of an overall understanding of the molecular interactions involved in IDD, we hope to better understand the pathogenetic mechanisms that drive the degenerative process. The purpose of this study is to obtain mRNAs, miRNAs, lncRNAs, and circRNAs associated with IDD gained from public databases and to establish an interaction network. According to the results of microarray analysis and bioinformatics analysis from the contrast of IDD and normal nucleus pulposus tissues, a total of 49 mRNAs, 10 miRNAs, 30 lncRNAs, and 4 circRNAs were obtained and a lncRNA/circRNA-miRNA-mRNA interaction network was constructed. NEAT1-miR-5100-COL10A1 and miR663AHG/HEIH/hsa-circ-0003600-miR-4741-HAS2/HYAL1/LYVE1 might be potential interaction axes of the molecular mechanism in IDD. The increased expression of NEAT1 might inhibit miR-5100 and subsequently upregulate the expression of COL10A1, which leads to IDD, while the increased expression of miR663AHG/HEIH/hsa-circ-0003600 might inhibit miR-4741 and indirectly upregulate HAS2/HYAL1/LYVE1, and leads to the protection from IDD. More interaction axes are to be exploited to provide theoretical bases for further study on IDD.Entities:
Year: 2021 PMID: 34307661 PMCID: PMC8263249 DOI: 10.1155/2021/6618834
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1The logical framework is mainly divided into data collection and screening, data analysis, and network construction. The datasets of mRNA, miRNA, lncRNA, and circRNA correlated to IDD were collected from the public database, and DEMs, DEGs, DELs, and DECs with significant expression differences were screened out. Bioinformatics analysis tools and databases were used to conduct regulatory prediction analysis on DEGs, DELs, and DECs and obtain miRNAs paired with them. DEMs was then matched to establish a complete lncRNA/circRNA-miRNA-mRNA network. Then, the network was used to conduct ceRNA analysis and functional enrichment analysis. IDD: intervertebral disc degeneration; DEM: differentially expressed miRNA; DEG: differentially expressed mRNA; DEL: differentially expressed lncRNA; DEC: differentially expressed circRNA; ceRNA: competitive endogenous RNA.
The basic information of the datasets obtained from GEO database.
| Dataset | Type of RNAs tested | Samples | Experimental group | Control group | Platform |
|---|---|---|---|---|---|
| GSE34095 | mRNA | 6 | Degenerative nucleus pulposus from IDD patients | Nucleus pulposus from scoliosis patients | GPL96 [HG-U133A] Affymetrix Human Genome U133A Array |
| GSE70362 | mRNA | 24 | Degenerative nucleus pulposus (Thompson grade III–V) | Degenerative nucleus pulposus (Thompson grade I–II) | GPL17810 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array [CDF: Brainarray HGU133Plus2_Hs_ENTREZG_v16] |
| GSE112216 | mRNA, lncRNA | 6 | Degenerative nucleus pulposus derived cells cocultured with adipose derived stem cell | Degenerative nucleus pulposus derived cells | GPL16686 [HuGene-2_0-st] Affymetrix Human Gene 2.0 ST Array [transcript (gene) version] |
| GSE114169 | mRNA | 8 | Degenerative nucleus pulposus cultured 1 week with Neurotropin | Degenerative nucleus pulposus cultured 1 week with none | GPL17077 Agilent-039494 SurePrint G3 Human GE v2 8x60K Microarray 039381 (Probe Name version) |
| GSE118927 | mRNA, lncRNA | 6 | Degenerative nucleus pulposus derived cells cocultured with adipose derived stem cell | Degenerative nucleus pulposus derived cells | GPL16686 [HuGene-2_0-st] Affymetrix Human Gene 2.0 ST Array [transcript (gene) version] |
| GSE124272 | mRNA | 16 | Peripheral blood from IDD patients | Peripheral blood from healthy people | GPL21185 Agilent-072363 SurePrint G3 Human GE v3 8x60K Microarray 039494 [Probe Name version] |
| GSE19943 | miRNA | 6 | Degenerative nucleus pulposus from IDD patients | Nucleus pulposus from scoliosis patients | GPL9946 Exiqon human miRCURY LNA™ microRNA Array V11.0 |
| GSE63492 | miRNA | 10 | Degenerative nucleus pulposus | Nondegenerative nucleus pulposus | GPL19449 Exiqon miRCURY LNA microRNA Array; 7th generation REV-hsa; mmu & rno (miRBase v18.0) |
| GSE116726 | miRNA | 6 | Degenerative nucleus pulposus from IDD patients | Nucleus pulposus from traumatic lumbar fracture | GPL20712 Agilent-070156 Human miRNA [miRNA version] |
| GSE56081 | lncRNA | 10 | Degenerative nucleus pulposus | Nondegenerative nucleus pulposus | GPL15314 Arraystar Human LncRNA microarray V2.0 (Agilent_033010 Probe Name version) |
| GSE67566 | circRNA | 10 | Degenerative nucleus pulposus | Nondegenerative nucleus pulposus | GPL19978 Agilent-069978 Arraystar Human CircRNA microarray V1 |
Top 20 upregulated and downregulated differentially expressed mRNAs.
| GSE70362 | |||||
|---|---|---|---|---|---|
| DEG |
| logFC | DEG |
| logFC |
| COL10A1 | 0.017000 | 2.32 | HIST1H2AE | 0.036200 | −1.48 |
| IGFBP3 | 0.007980 | 2.24 | Scgb2a2 | 0.008330 | −1.50 |
| SMIM3 | 0.003260 | 1.78 | Mt1m | 0.012000 | −1.50 |
| LMO2 | 0.000055 | 1.75 | FOXQ1 | 0.000920 | −1.61 |
| GDF15 | 0.000670 | 1.73 | MT1G | 0.002230 | −1.79 |
| TFPI | 0.002200 | 1.63 | SCGB1D2 | 0.026100 | −1.83 |
| CCND1 | 0.000055 | 1.60 | HOPX | 0.001200 | −1.86 |
| NPTX2 | 0.032000 | 1.55 | KRT19 | 0.009330 | −1.92 |
| EMILIN1 | 0.000110 | 1.51 | SDR16C5 | 0.000174 | −1.92 |
| TNFAIP6 | 0.002250 | 1.43 | IBSP | 0.005660 | −2.22 |
DEG: differentially expressed mRNA.
Top 20 upregulated and downregulated differentially expressed miRNAs.
| GSE63492 | GSE116726 | ||||
|---|---|---|---|---|---|
| DEM |
| logFC | DEM | Adj. | logFC |
| hsa-miR-4287 | 0.004497 | 5.81 | hsa-miR-29c-3p | 0.000033 | 2.58 |
| hsa-miR-3150a-3p | 0.000012 | 5.03 | hsa-miR-187-3p | 0.000001 | 2.52 |
| hsa-miR-3157-3p | 0.010912 | 4.90 | hsa-miR-141-3p | 0.000001 | 2.52 |
| hsa-miR-660-5p | 0.00199 | 4.80 | hsa-miR-455-5p | 0.000009 | 2.52 |
| hsa-miR-887-3p | 0.000105 | 4.05 | hsa-miR-34a-5p | 0.000065 | 2.46 |
| hsa-miR-5010-5p | 0.026553 | 4.03 | hsa-miR-610 | 0.000079 | 2.44 |
| hsa-miR-933 | 0.00739 | 3.43 | hsa-miR-139-5p | 0.000378 | 2.42 |
| hsa-miR-3127-5p | 0.004452 | 3.35 | hsa-miR-223-5p | 0.000001 | 2.41 |
| hsa-miR-4450 | 0.002228 | 3.24 | hsa-miR-338-3p | 0.000008 | 2.41 |
| hsa-miR-516a-5p | 0.000229 | 3.15 | hsa-miR-127-5p | 0.000001 | 2.40 |
| hsa-miR-193a-5p | 0.01867 | −2.65 | hsa-miR-6857-5p | 0.000999 | −1.74 |
| hsa-miR-1246 | 0.036306 | −2.92 | hsa-miR-3654 | 0.000581 | −1.85 |
| hsa-miR-4454 | 0.017803 | −2.97 | hsa-miR-204-5p | 0.00703 | −2.26 |
| hsa-miR-4327 | 0.004021 | −3.02 | hsa-miR-590-5p | 0.000082 | −2.34 |
| hsa-miR-155-5p | 0.017538 | −3.22 | hsa-miR-181c-5p | 0.000292 | −2.40 |
| hsa-miR-196b-5p | 0.013547 | −3.43 | hsa-miR-378a-5p | 0.000002 | −2.46 |
| hsa-miR-3648 | 0.000614 | −3.76 | hsa-miR-410-5p | 0.000001 | −2.49 |
| hsa-miR-486-3p | 0.008002 | −4.39 | hsa-miR-376a-5p | 0.000001 | −2.50 |
| hsa-miR-125b-1-3p | 0.000444 | −4.69 | hsa-miR-486-5p | 0.000003 | −2.77 |
| hsa-miR-1184 | 0.000544 | −4.85 | hsa-miR-32-5p | 0.000001 | −2.81 |
DEM: differentially expressed miRNA.
Top 20 upregulated and downregulated differentially expressed lncRNAs and circRNAs.
| GSE56081 | GSE67566 | ||||
|---|---|---|---|---|---|
| DEL | Adj. | logFC | DEC | Adj. | logFC |
| TRPC7-AS1 | 6.55 | 6.61 | hsa_circRNA_101852 | 3.92 | 2.98 |
| MIR4458HG | 5.56 | 1.40 | hsa_circRNA_101853 | 6.98 | 2.93 |
| GAS5 | 4.30 | 1.40 | hsa_circRNA_101139 | 6.98 | 2.92 |
| CBR3-AS1 | 4.30 | 1.40 | hsa_circRNA_103890 | 1.72 | 2.86 |
| ADPGK-AS1 | 2.67 | 1.40 | hsa_circRNA_400019 | 3.87 | 2.84 |
| SNHG5 | 2.67 | 1.40 | hsa_circRNA_102324 | 1.00 | 2.78 |
| ADARB2-AS1 | 4.17 | 1.39 | hsa_circRNA_104703 | 1.24 | 2.72 |
| LINC00431 | 4.68 | 1.39 | hsa_circRNA_104600 | 7.51 | 2.68 |
| MCCC1-AS1 | 8.89 | 1.39 | hsa_circRNA_100604 | 1.57 | 2.68 |
| MALAT1 | 6.58 | 1.07 | hsa_circRNA_100018 | 1.67 | 2.61 |
| LINC01405 | 9.52 | −3.04 | hsa_circRNA_105031 | 1.18 | −2.83 |
| LINC00884 | 5.11 | −3.12 | hsa_circRNA_101370 | 1.82 | −2.86 |
| HAND2-AS1 | 3.47 | −3.21 | hsa_circRNA_104019 | 2.04 | −2.97 |
| EFCAB6-AS1 | 2.96 | −3.39 | hsa_circRNA_104630 | 2.41 | −3.04 |
| LINC00689 | 2.87 | −3.63 | hsa_circRNA_101709 | 1.18 | −3.04 |
| MAPT-AS1 | 6.53 | −5.12 | hsa_circRNA_101557 | 1.96 | −.05 |
| IL10RB-AS1 | 9.48 | −5.54 | hsa_circRNA_103838 | 6.98 | −3.06 |
| VPS13A-AS1 | 1.81 | −6.01 | hsa_circRNA_102116 | 1.92 | −3.18 |
| LINC00957 | 7.33 | −6.28 | hsa_circRNA_104508 | 2.19 | −3.26 |
| HOTAIR | 6.47 | −7.21 | hsa_circRNA_101645 | 1.60 | −3.30 |
DEL: differentially expressed lncRNA; DEC: differentially expressed circRNA.
Figure 2Analysis of differentially expressed RNAs in each dataset. (a) Hierarchical clustering and heat map analysis of differentially expressed RNAs in each dataset. (b) Venn diagram of differentially expressed miRNAs between GSE63492 and GSE116726. (c) A diagram that exhibits the expressions of the 33 miRNAs in the two datasets, and 14 DEMs with consistent expression were ultimately selected, among which 9 were upregulated and 5 were downregulated.
Gene ontology enrichment analysis of 80 DEGs and 49 genes that formed the miRNA–mRNA interaction relationship.
| Sample group | Category | Term | Count |
| Genes |
|---|---|---|---|---|---|
| 80 | CC | Extracellular exosome | 25 | 0.000123351 | GALNT3; LPL; HYAL1; ACTC1; HIST1H2AE; QDPR; SELENBP1; NPR3; TMEM27; EMILIN1; LYVE1; KRT19; TEX14; PTGDS; VAMP8; DMKN; AOX1; GDF15; CFD; SPON2; NQO1; DEFB1; IGFBP3; DCXR; HIST1H4H |
| 80 | CC | Extracellular space | 16 | 0.000207983 | IBSP; HYAL1; LPL; ACTC1; CYTL1; SELENBP1; PTHLH; TNFAIP6; PTGDS; SCGB1D2; TFPI; SPON2; CFD; GDF15; IGFBP3; DEFB1 |
| 49 | MF | Virus receptor activity | 4 | 0.00065 | HYAL1; LDLR; CD80; EFNB2 |
| 80 | BP | Cellular response to zinc ion | 3 | 0.002491898 | MT1M; MT1G; MT1F |
| 80 | BP | Negative regulation of growth | 3 | 0.002491898 | MT1M; MT1G; MT1F |
| 80 | MF | Virus receptor activity | 4 | 0.002592014 | HYAL1; LDLR; CD80; EFNB2 |
| 80 | CC | Extracellular region | 15 | 0.003781513 | IBSP; LPL; EMILIN1; PTHLH; PTGDS; NPTX2; DMKN; TFPI; TREM1; CFD; GDF15; IGFBP3; DEFB1; HIST1H4H; COL10A1 |
| 80 | BP | Viral entry into host cell | 4 | 0.003840079 | LDLR; CD80; VAMP8; EFNB2 |
| 80 | BP | Cell adhesion | 7 | 0.009200697 | IBSP; TNFAIP6; LYVE1; CYP1B1; EFNB2; SPON2; EMILIN1 |
| 49 | MF | Hyaluronan synthase activity | 2 | 0.009680585 | HYAL1; HAS2 |
| 80 | MF | Hyaluronan synthase activity | 2 | 0.015548781 | HYAL1; HAS2 |
| 49 | BP | Viral entry into host cell | 3 | 0.017061685 | LDLR; CD80; EFNB2 |
| 49 | BP | Hyaluronan biosynthetic process | 2 | 0.017380591 | HYAL1; HAS2 |
| 80 | BP | Cell-cell signaling | 5 | 0.017725805 | PTHLH; TNFAIP6; CD80; EFNB2; GDF15 |
| 80 | TH | Neral absorption | 3 | 0.019704118 | MT1M; MT1G; MT1F |
| 49 | MF | Transcriptional activator activity, RNA polymerase II transcription regulatory region sequence spec | 3 | 0.022287725 | LMO2; GATA6; FOXF2 |
| 80 | BP | Response to estrogen | 3 | 0.026997667 | KRT19; CCND1; GATA6 |
| 80 | BP | Hyaluronan biosynthetic process | 2 | 0.027195604 | HYAL1; HAS2 |
| 49 | BP | Cell adhesion | 5 | 0.027213497 | IBSP; LYVE1; CYP1B1; EFNB2; SPON2 |
| 80 | MF | Transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding | 3 | 0.027502988 | T; GATA6; FOXF2 |
| 49 | BP | Response to ethanol | 3 | 0.028347603 | ACTC1; CCND1; NQO1 |
| 49 | BP | Retinal metabolic process | 2 | 0.029614391 | CYP1B1; SDR16C5 |
| 49 | MF | Transcription factor binding | 4 | 0.031391824 | HYAL1; CCND1; GATA6; FOXF2 |
| 80 | BP | Cellular response to interleukin-1 | 3 | 0.031774689 | HYAL1; TFPI; HAS2 |
| 49 | BP | Positive regulation of urine volume | 2 | 0.032043246 | HAS2; NPR3 |
| 49 | BP | Nitric oxide biosynthetic process | 2 | 0.032043246 | CYP1B1; NQO1 |
| 49 | BP | Positive regulation of angiogenesis | 3 | 0.033505165 | HYAL1; CYP1B1; GATA6 |
| 49 | BP | Positive regulation of transcription from RNA polymerase II promoter | 7 | 0.033985253 | DLX3; LMO2; GATA6; EBF1; FOXF2; CYTL1; ZEB2 |
| 49 | BP | Hyaluronan catabolic process | 2 | 0.036883166 | HYAL1; LYVE1 |
| 49 | BP | Response to drug | 4 | 0.040149506 | LPL; ACTC1; CCND1; GATA6 |
| 80 | CC | Transcription factor complex | 4 | 0.040958701 | LMO2; GATA6; FOXF2; PDLIM1 |
| 80 | BP | Extracellular matrix organization | 4 | 0.041931952 | IBSP; FOXF2; EMILIN1; COL10A1 |
| 49 | BP | Cellular response to platelet-derived growth factor stimulus | 2 | 0.044098781 | HYAL1; HAS2 |
| 80 | BP | Retinal metabolic process | 2 | 0.046173764 | CYP1B1; SDR16C5 |
| 80 | BP | Response to estradiol | 3 | 0.049819454 | CCND1; TFPI; NQO1 |
| 80 | BP | Nitric oxide biosynthetic process | 2 | 0.049925405 | CYP1B1; NQO1 |
| 80 | BP | Positive regulation of urine volume | 2 | 0.049925405 | HAS2; NPR3 |
MF: molecular function; BP: biological process; CC: cellular component.
Figure 3The bubble diagram of gene ontology function enrichment analysis of 80 DEGs and 49 genes that formed the miRNA–mRNA interaction relationship.
Figure 4Protein-protein interaction network. Network nodes represent the proteins produced by a single protein-coding gene locus. Blue represents the proteins that jointly contribute to a shared function but do not necessarily mean that they are physically binding each other. Grey represents the proteins without association. Triangle means upregulated expression, whereas arrow means downregulated expression.
lncRNA/circRNA–miRNA–mRNA relationship.
| DEM | DEG | DEL | DEC |
|---|---|---|---|
| hsa-miR-3127-5p | CA12; HYAL1; LYVE1; PNMAL1; RAPGEF5; SDR16C5; ZNF185 | LINC00680; HOTAIR; GLIDR; LOC148696 | hsa_circ_0044177; hsa_circ_0001666 |
| hsa-miR-3161 | ACTC1; C4orf32; CA12; DMKN; EFNB2; HAS2; IBSP; SHISA2; ST8SIA1 | MIR663AHG; GABPB1-AS1 | — |
| hsa-miR-4462 | FAM189A2; LDLR; QDPR; SPON2 | — | hsa_circ_0056390 |
| hsa-miR-4741 | CA12; DMKN; HAS2; HYAL1; LDLR; LYVE1; MT1G; SDR16C5; ST8SIA1 | MIR663AHG; HEIH | hsa_circ_0003600 |
| hsa-miR-4758-5p | ABLIM1 | — | — |
| hsa-miR-518a-5p | ABLIM1; C4orf32; CA12; EFNB2; FOXQ1; HIST1H2AE; IBSP; LDLR; LYVE1; PNMAL1; RAPGEF5; SCRN1; SHISA2; SPTSSB; ST8SIA1; TMEM71 | GABPB1-AS1; HAND2-AS1; DLG1-AS1; TUSC8 | — |
| hsa-miR-642a-3p | C4orf32; EFNB2; FAM189A2; FOXF2; HOPX; LPL; LYVE1; PNMAL1; ZNF185 | MIR663AHG; HOXD-AS2 | — |
| hsa-miR-486-3p | CCND1; CFD; CYP1B1; DLX3; DUSP5; NPR3; NPTX2; PTGDS; SMIM3 | UCA1; C14orf132; LINC00638; DLEU1; LOC100630923; LINC01123; LOC642846 | — |
| hsa-miR-5100 | CD1D; CD80; CFD; CNIH3; COL10A1; CYP1B1; CYTL1; EBF1; GATA6; NPR3; NQO1; SLITRK4; SMIM3; ZEB2 | LINC00475; SOX2-OT; NEAT1; SNHG12; GAS5; AGAP2-AS1; TARID | — |
| hsa-miR-623 | CCND1; CD80; CYP1B1; EBF1; GATA6; LMO2 | NEAT1; LINC00560; ADIPOQ-AS1; MALAT1; HOTTIP; LINC00475 | — |
Figure 5Competing endogenous RNA interaction network of lncRNA/circRNA–miRNA–mRNA. Yellow represents lncRNA, green represents circRNA, red represents miRNA, and blue represents mRNA. Triangle means upregulated expression, whereas arrow means downregulated expression.
Figure 6Schematic diagram of hyaluronic acid-related IDD molecular mechanism. The integral membrane dual-action glycosyltransferase proteins hyaluronan synthases 1–3 (HAS1-3) mediate the polymerization of glucuronic acid (GlcA) with N-acetylglucosamine (GlcNAc) to form HA. The resulting polymer has the arrangement [-4GlcA-1,3GlcNAc-]n. LYVE1, HMMR, STAB2, and CD44 together form the HAR complex. High molecular weight HA is tethered to the cell surface by HA receptors and the GPI-linked hyaluronidase 2 (HYAL2) to form a HA : HAR : HYAL2 complex in the plasma membrane that localizes to caveolae, continuing to complete the degradation of HA. In the acidic environment of the lysosome, hyaluronidase 1 (HYAL1) could hydrolyze large 50 disaccharide unit HA fragments to 2 disaccharide units. HAS2, HYAL1, and LYVE1 may be negatively regulated by miR-4741, while mi663ahg/HEIH (lncRNA) and hsa-circ-0003600 (circRNA) may competitively be bound on miR-4741 to act as ceRNAs, correcting the negative regulation of miR-4741 to prevent IDD.
Figure 7Schematic diagram of COL10A1-related IDD molecular mechanism. The red line represents positive regulation, the green line represents negative regulation, and the arrow represents the direction of regulation. The solid line represents the verified regulatory relationship, and the dashed line represents the regulatory hypothesis proposed in this study. COL10A1 may be negatively regulated by miR-5100, while lncRNA LINC00475, SOX2-OT, NEAT1, SNHG12, GAS5, AGAP2-AS1, and TARID may act as ceRNA for competitively binding miR-5100 and thus correcting the negative regulation of miR-5100, inducing IDD.